2022 Nobel Laureate in Chemistry: Using chemical technology to disrupt cancer treatment, founding the company with hundreds of millions of dollars in financing, and has launched clinical trials

On October 5, Carolyn R.

"I guide myself"

Carolyn Bertozzi graduated from Harvard University in 1988, and since then, she has been studying for a PhD at the University of California, Berkeley, and in her third year, her supervisor was unable to give normal research guidance due to rectal cancer, and a year later her supervisor left UC Berkeley for Stanford University

Carolyn Bertozzi joined the University of California, Berkeley as an assistant professor in 1996, was promoted to associate professor in 1999, became professor in 2002, was elected to the American Academy of Arts and Sciences (AAAS) in 2003, and was elected to the National Academy of Sciences (NAS)

Pioneering bioorthogonal chemistry

In 2001, K.

In 2003, Carolyn Bertozzi proposed Bioorthogonal Chemistry, which enables foreign molecules or functional groups to react quickly and efficiently in the complex environment of living organisms, without affecting normal intermolecular reactions in living organisms

From laboratory to clinical treatment

Carolyn Bertozzi's lab uses biological orthogonal reactions to track molecular interactions in organisms and their effects on disease, and to label and image

Based on these findings, Carolyn Bertozzi founded a biotechnology company called Palleon Pharmaceuticals in 2015 to develop sugar-mediated immunomodulation for cancer and inflammatory diseases, such as the formation of sialidase with PD-L1 or HER2 antibodies to form fusion proteins for a two-pronged anti-cancer effect

In 2020, Carolyn Bertozzi's lab published a paper in the journal Nature to develop a lysosome-targeted chimeric technology (LYTAC), a new protein degradation platform that solves the problem of selective degradation of proteins secreted outside the cell and proteins on cell membranes, which was previously difficult to achieve, and makes up for the fact that PROTAC can only degrade intracellular protein domains

Based on this research, Carolyn Bertozzi founded a biotechnology company

In August 2021, Lycia partnered with Eli Lilly to advance technology discovery, development, and commercialization

Cooperation with China

On June 28, 2022, Henlius Fuhong (2696.

It is reported that Henlius Fuhong obtained the exclusive license of these two products in China, including Hong Kong, Macao and Taiwan; Palleon reserves rights in other global regions; Palleon will receive a down payment and a milestone payment

At present, Palleon has a total of 4 oncology research and development pipelines, of which the fastest progress is E-602, which is in phase 1/2 clinical trial

The remaining three pipelines are bifunctional anti-PD-L1 antibody-sialidase fusion protein, bifunctional anti-HER2 antibody-sialidase fusion protein, and an undisclosed tumor-associated antigen-sialidase fusion protein

Resources:

https://lyciatx.
com/

https://palleonpharma.
com/news/

Nobel Prize in Chemistry: 81-year-old "Not Smart" spanned twenty-one years of two awards